Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., trading under ticker LACQ, filed an S-1 registration statement with the SEC on January 17, 2024, bearing accession number 0001493152-24-002548. The company traces its public-market origins to Leisure Acquisition Corp., a blank-check SPAC that completed its IPO in 2019. Ensysce operates in the biopharmaceutical sector, with a focus on abuse-deterrent drug formulations. The January 2024 S-1 represents a registration filing in the post-combination phase of the company's public-company lifecycle. For complete filing history, sponsor details, and real-time status updates on LACQ and hundreds of other SPAC vehicles, sign up for full data access at SpacDesk.